Walsh & Associates’s ResMed RMD Stock Holding History

Walsh & Associates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.4K	Hold	120	–	–	0.02%	158
2026 Q1	$26.9K	Hold	120	–	–	0.03%	141
2025 Q4	$28.9K	Buy	+120	New	+$30.7K	0.03%	141

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Walsh & Associates's RMD Position: Q2 2026 in Review

Walsh & Associates held its ResMed (RMD) position steady in Q2 2026 at 120 shares worth $23.4K. The position accounts for 0.02% of the portfolio, ranked #158.

Walsh & Associates first reported a position in RMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $28.9K in Q4 2025. 879 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Walsh & Associates held 120 shares of ResMed worth $23.4K as of Q2 2026.
Walsh & Associates left its ResMed share count unchanged in Q2 2026.
ResMed made up 0.02% of Walsh & Associates's portfolio in Q2 2026, its #158 holding.
Walsh & Associates first reported a position in ResMed in Q4 2025 and has held it in 3 quarters since.
Walsh & Associates's ResMed position peaked at $28.9K in Q4 2025.
879 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.